The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target ...
Earnings Per Share (EPS) of $1.20, surpassing the estimated $1.17, reflecting the company’s ability to exceed market expectations. Revenue reached approximately $34.1 billion, exceeding forecasts and ...
We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...
Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
Q4 2024 Management View CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing ...
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...
Through its annual giving campaign, The Hanover Insurance Group, Inc. (NYSE: THG) and its employees raised over $1.5 million for nonprofit organizations across the country, including United Way, ...
Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring ...
"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which ...